Johnson & Johnson (NYSE:JNJ) Stake Lifted by Tidal Investments LLC

Tidal Investments LLC grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 11.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 186,860 shares of the company's stock after purchasing an additional 18,605 shares during the quarter. Tidal Investments LLC's holdings in Johnson & Johnson were worth $30,283,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of JNJ. Innealta Capital LLC acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $27,000. Highline Wealth Partners LLC acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $31,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth $35,000. Mowery & Schoenfeld Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company's stock valued at $40,000 after acquiring an additional 91 shares in the last quarter. Finally, Activest Wealth Management acquired a new position in shares of Johnson & Johnson during the third quarter worth about $40,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

JNJ has been the topic of a number of analyst reports. Citigroup lowered their price objective on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a report on Wednesday. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 16th. StockNews.com raised Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 14th. Bank of America reaffirmed a "neutral" rating and set a $166.00 price objective on shares of Johnson & Johnson in a research note on Tuesday. Finally, Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a research note on Wednesday, November 6th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $174.73.

Johnson & Johnson Stock Down 0.3 %

Johnson & Johnson stock traded down $0.41 during midday trading on Thursday, hitting $146.23. 6,174,458 shares of the stock were exchanged, compared to its average volume of 7,118,662. The company has a 50 day moving average price of $157.29 and a two-hundred day moving average price of $156.35. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The firm has a market cap of $352.07 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.66 and a beta of 0.51. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period in the previous year, the business earned $2.66 EPS. Johnson & Johnson's revenue for the quarter was up 5.2% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. Johnson & Johnson's payout ratio is 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now directly owns 1,000 shares in the company, valued at $147,220. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.